Get started
Fulcrum Therapeutics, Inc.Fulcrum Therapeutics, Inc.Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

FULC chart


Full chart

FULC upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪189.47 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.20 USD
Net income (FY)
‪−9.72 M‬ USD
Revenue (FY)
‪80.00 M‬ USD
Shares float
‪47.85 M‬
Beta (1Y)
0.30

Employees


Employees (FY)
45
Change (1Y)
−31 −40.79%
Revenue / Employee (1Y)
‪1.78 M‬ USD
Net income / Employee (1Y)
‪−216.11 K‬ USD

About Fulcrum Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Alexander C. Sapir
Website
fulcrumtx.com
Headquarters
Cambridge
Founded
2015
FIGI
BBG00DDY1RK9
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

FULC news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as FULC.

Frequently Asked Questions


The current price of FULC is 3.49 USD — it has decreased by −2.23% in the past 24 hours. Watch Fulcrum Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Fulcrum Therapeutics, Inc. stocks are traded under the ticker FULC.
FULC stock has risen by 15.08% compared to the previous week, the month change is a 7.01% rise, over the last year Fulcrum Therapeutics, Inc. has showed a −50.64% decrease.
We've gathered analysts' opinions on Fulcrum Therapeutics, Inc. future price: according to them, FULC price has a max estimate of 14.00 USD and a min estimate of 2.00 USD. Watch FULC chart and read a more detailed Fulcrum Therapeutics, Inc. stock forecast: see what analysts think of Fulcrum Therapeutics, Inc. and suggest that you do with its stocks.
FULC reached its all-time high on Sep 21, 2021 with the price of 33.10 USD, and its all-time low was 2.25 USD and was reached on Apr 12, 2023. View more price dynamics on FULC chart.
See other stocks reaching their highest and lowest prices.
FULC stock is 3.69% volatile and has beta coefficient of 0.30. Track Fulcrum Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Fulcrum Therapeutics, Inc. there?
Today Fulcrum Therapeutics, Inc. has the market capitalization of ‪189.47 M‬, it has increased by 22.30% over the last week.
Yes, you can track Fulcrum Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Fulcrum Therapeutics, Inc. is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
FULC earnings for the last quarter are −0.31 USD per share, whereas the estimation was −0.28 USD resulting in a −10.06% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about Fulcrum Therapeutics, Inc. earnings.
Fulcrum Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
FULC net income for the last quarter is ‪−16.57 M‬ USD, while the quarter before that showed ‪−21.70 M‬ USD of net income which accounts for 23.64% change. Track more Fulcrum Therapeutics, Inc. financial stats to get the full picture.
No, FULC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 25, 2025, the company has 45 employees. See our rating of the largest employees — is Fulcrum Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Fulcrum Therapeutics, Inc. EBITDA is ‪−18.19 M‬ USD, and current EBITDA margin is −22.80%. See more stats in Fulcrum Therapeutics, Inc. financial statements.
Like other stocks, FULC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Fulcrum Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Fulcrum Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Fulcrum Therapeutics, Inc. stock shows the sell signal. See more of Fulcrum Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.